Background: Pegaptanib sodium, the first aptamer therapeutic approved for use and the first antiangiogenic agent used to treat ocular neovascular disease, acts by inhibiting the 165 isoform of vascular endothelial growth factor believed primarily responsible for pathologic ocular neovascularization and vascular permeability. Objective: To briefly present the pharmacology, clinical efficacy and safety, and role of pegaptanib in treating ocular neovascular diseases. Methods: A systematic literature review and synopsis. Results/conclusion: After more than 10 years in development, clinical trials have shown pegaptanib efficacy in treating choroidal neovascularization of age-related macular degeneration. Its excellent ocular and systemic safety profiles have been confirmed in up to 3 years of experience. Early phase, well-controlled studies also suggest therapeutic benefit in diabetic retinopathy and retinal vein occlusion.

Original languageEnglish
Pages (from-to)499-508
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Issue number3
StatePublished - Feb 2008


  • Age-related macular degeneration
  • Aptamer
  • Choroidal neovascularization
  • Pegaptanib
  • Vascular endothdial growth factor


Dive into the research topics of 'Pegaptanib sodium for the treatment of age-related macular degeneration'. Together they form a unique fingerprint.

Cite this